Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
Protocol ID
ANBL1232
Disease (Sub Disease)
Ganglioneuroblastoma
Neuroblastoma
Neuroblastoma
Diagnosis Stage
Relapse/refractory
Location
NSW, QLD, WA, SA, NZ
Sponsor
Children's Oncology Group
Collaborators
National Cancer Institute (NCI)
Links
Trial Status
Open
Sites
The Children's Hospital at Westmead
John Hunter Children's Hospital
Perth Children's Hospital
Queensland Children's Hospital
Sydney Children's Hospital
Women's & Children's Hospital
Christchurch Hospital
Starship Hospital
John Hunter Children's Hospital
Perth Children's Hospital
Queensland Children's Hospital
Sydney Children's Hospital
Women's & Children's Hospital
Christchurch Hospital
Starship Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
up to 18 months
International registry ID's
NCT02176967
| Study Title | Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma |
|---|---|
| Protocol ID | ANBL1232 |
| Disease (Sub Disease) | Ganglioneuroblastoma Neuroblastoma |
| Diagnosis Stage | Relapse/refractory |
| Location | NSW / QLD / WA / SA / NZ |
| Sponsor | Children's Oncology Group |
| Collaborators | National Cancer Institute (NCI) |
| Links | https://clinicaltrials.gov/ct2/show/NCT02176967 |
| Trial Status | Open |
| Trial Open Date | 28/07/2014 |
| Sites | The Children's Hospital at Westmead / John Hunter Children's Hospital / Perth Children's Hospital / Queensland Children's Hospital / Sydney Children's Hospital / Women's & Children's Hospital / Christchurch Hospital / Starship Hospital |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | up to 18 months |
| International registry ID's | NCT02176967 |